Scarica l'app Stockscreener
5.92
0.17%
0.010
Dopo l'orario di chiusura:
5.92
Precedente Chiudi:
$5.91
Aprire:
$5.91
Volume 24 ore:
928
Relative Volume:
0.05
Capitalizzazione di mercato:
$12.73M
Reddito:
$7.88M
Utile/perdita netta:
$-69.20M
Rapporto P/E:
-3.235
EPS:
-1.83
Flusso di cassa netto:
$-69.73M
1 W Prestazione:
+2.96%
1M Prestazione:
-2.47%
6M Prestazione:
-49.68%
1 anno Prestazione:
-59.86%
Intervallo 1D:
$5.91
$6.04
Intervallo di 1 settimana:
$5.52
$6.21
Portata 52W:
$5.20
$15.60
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Nome
Bolt Biotherapeutics Inc
Settore
Industria
Telefono
650-665-9295
Indirizzo
900 CHESAPEAKE DRIVE, REDWOOD CITY
Confronta BOLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.92 | 12.73M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Iniziato | Guggenheim | Buy |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
Bolt Biotherapeutics Inc Borsa (BOLT) Ultime notizie
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 91.6% - Defense World
Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World
Citadel Advisors LLC Takes Position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
BOLT Trading Temporarily Halted as Company Awaits News | BOLT St - GuruFocus
BOLT Trading Temporarily Halted as Company Awaits News | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Announces Reverse Stock Split - TipRanks
Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025 - MarketScreener
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
BOLT Announcement: Bronstein, Gewirtz and Grossman, LLC Announces Investor Securities Fraud Class Action Lawsuit Filed Against Bolt Biotherapeutics, Inc - ACCESS Newswire
BOLT Announcement: Bronstein, Gewirtz and Grossman, LLC Announces Investor Securities Fraud Class Action Lawsuit Filed Against Bolt Biotherapeutics, Inc. and Chance to Actively Participate - ACCESS Newswire
Bolt Biotherapeutics Approves Key Governance Changes - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus
Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus
Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World
Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN
BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus
BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus
BOLT Stock Target Price Revised to $1 Amid Recent Developments | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News
Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 Beats Estimate, Revenue Surpasses Expectations at $1.2 Million - GuruFocus
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune
About Us - FinancialContent
Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia
Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus
New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus
Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India
Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq
Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan
Bolt Biotherapeutics Inc Azioni (BOLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bolt Biotherapeutics Inc Azioni (BOLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Quinn William P. | President, CEO and CFO |
Dec 16 '24 |
Buy |
0.50 |
2,500 |
1,241 |
41,272 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):